Published in BMJ on January 24, 2005
Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ (2008) 4.09
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf (2012) 2.11
ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology (2007) 2.09
Modern antipsychotic drugs: a critical overview. CMAJ (2005) 1.98
Antipsychotics for people with dementia. BMJ (2008) 1.45
Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ (2008) 1.34
Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ (2008) 1.21
Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med (2007) 1.05
Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr (2012) 1.01
Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging (2014) 0.98
Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol (2008) 0.95
Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. Eur Neuropsychopharmacol (2013) 0.91
Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J (2014) 0.89
Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol (2012) 0.88
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology (2015) 0.87
Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology (Berl) (2010) 0.87
Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry (2015) 0.86
The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs. Am J Epidemiol (2014) 0.82
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat (2007) 0.82
Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. PLoS One (2014) 0.81
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. PLoS One (2016) 0.81
Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea. PLoS One (2015) 0.80
Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. Pharmacoepidemiol Drug Saf (2014) 0.79
Beyond the Black Box: What is The Role for Antipsychotics in Dementia? Curr Psychiatr (2008) 0.78
Effect of different antipsychotic drugs on short-term mortality in stroke patients. Medicine (Baltimore) (2014) 0.78
Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Psychopharmacology (Berl) (2007) 0.78
Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging (2015) 0.77
Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia. Indian J Psychiatry (2009) 0.77
Approach to managing behavioural disturbances in dementia. Can Fam Physician (2006) 0.75
Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. Neuropsychiatr Dis Treat (2006) 0.75
Clinical pharmacology and vascular risk. Open Neurol J (2010) 0.75
Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons. J Am Heart Assoc (2015) 0.75
Prevalence of, and Resident and Facility Characteristics Associated With Antipsychotic Use in Assisted Living vs. Long-Term Care Facilities: A Cross-Sectional Analysis from Alberta, Canada. Drugs Aging (2016) 0.75
Treatment advances in Alzheimer's disease based on the oxidative stress model. F1000 Med Rep (2009) 0.75
Improving physical health monitoring for patients with chronic mental health problems who receive antipsychotic medications. BMJ Qual Improv Rep (2016) 0.75
Subarachnoid Hemorrhage and Long-Term Stroke Risk After Traumatic Brain Injury. Neurohospitalist (2016) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
Short-term prognosis after emergency department diagnosis of TIA. JAMA (2000) 5.00
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry (2004) 3.71
New evidence for stroke prevention: scientific review. JAMA (2002) 3.70
Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol (2003) 3.51
Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet (2000) 3.35
Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ (2004) 3.29
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry (2001) 2.74
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry (2003) 2.50
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ (2002) 2.41
The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology (2004) 2.34
Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry (2003) 2.18
Nose bleeds associated with use of risperidone. BMJ (2004) 1.61
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ (2004) 1.43
The use of atypical antipsychotics in nursing homes. J Clin Psychiatry (2003) 1.36
Surveillance for stroke in Canada. Health Rep (1994) 1.30
Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist (1993) 1.28
Management and outcomes of transient ischemic attacks in Ontario. CMAJ (2004) 1.27
Delirium. BMJ (2002) 1.13
Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am (2002) 1.07
CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ (2004) 1.05
Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clin Geriatr Med (2001) 0.93
Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc (2004) 0.91
PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab (2001) 0.86
Screening for serious mental illness in the general population. Arch Gen Psychiatry (2003) 15.75
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
A meta-analysis of cytokines in major depression. Biol Psychiatry (2009) 7.16
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 6.73
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ (2005) 6.57
Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA (2002) 6.30
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes (2008) 6.00
Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes (2009) 5.66
Pay for performance in commercial HMOs. N Engl J Med (2006) 5.52
An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction. Circulation (2006) 5.35
Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA (2011) 5.33
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 5.25
National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA (2011) 5.16
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Prescription drug use in pregnancy. Am J Obstet Gynecol (2004) 4.92
Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation (2007) 4.74
Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA (2008) 4.74
An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation (2006) 4.52
Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet (2006) 4.42
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg (2009) 4.39
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med (2013) 4.35
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Physician clinical performance assessment: prospects and barriers. JAMA (2003) 4.16
Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA (2003) 4.00
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ (2005) 3.94
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
Behavioral health insurance parity for federal employees. N Engl J Med (2006) 3.77
Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry (2004) 3.71
Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med (2007) 3.71
Health plan members' views about disclosure of medical errors. Ann Intern Med (2004) 3.69
Variability in the measurement of hospital-wide mortality rates. N Engl J Med (2010) 3.65
Preventing pressure ulcers: a systematic review. JAMA (2006) 3.64
Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA (2004) 3.61
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg (2009) 3.45
Effect of socioeconomic status on treatment and mortality after stroke. Stroke (2002) 3.44
Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med (2009) 3.43
Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med (2007) 3.34
Recent declines in hospitalizations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing challenges. Circulation (2010) 3.32
An administrative claims measure suitable for profiling hospital performance based on 30-day all-cause readmission rates among patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes (2011) 3.31
Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation (2013) 3.30
Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med (2008) 3.29
Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ (2004) 3.29
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA (2009) 3.21
Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA (2006) 3.20
Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Stat Med (2007) 3.20
Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv (2002) 3.15
Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc (2004) 3.12
The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med (2012) 3.10
Medical illness and the risk of suicide in the elderly. Arch Intern Med (2004) 3.09
Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med (2008) 3.06
Nonemergency PCI at hospitals with or without on-site cardiac surgery. N Engl J Med (2013) 2.98
Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ (2011) 2.97
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med (2009) 2.96
Treatment of pressure ulcers: a systematic review. JAMA (2008) 2.96
Solvent exposures and Parkinson disease risk in twins. Ann Neurol (2011) 2.92
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med (2013) 2.81
Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ (2006) 2.71
Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA (2011) 2.67
Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) (2007) 2.62
Quality measurement in adult cardiac surgery: part 1--Conceptual framework and measure selection. Ann Thorac Surg (2007) 2.60
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ (2003) 2.59
Quality measurement in adult cardiac surgery: part 2--Statistical considerations in composite measure scoring and provider rating. Ann Thorac Surg (2007) 2.59
Regionalization and the underuse of angiography in the Veterans Affairs Health Care System as compared with a fee-for-service system. N Engl J Med (2003) 2.57
Comparison of clinical and administrative data sources for hospital coronary artery bypass graft surgery report cards. Circulation (2007) 2.55
Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med (2010) 2.51
Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA (2012) 2.47
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med (2008) 2.46
Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol (2009) 2.45
Reader's guide to critical appraisal of cohort studies: 1. Role and design. BMJ (2005) 2.43
Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney Int (2013) 2.42
Massachusetts cardiac surgery report card: implications of statistical methodology. Ann Thorac Surg (2005) 2.40
Prolonged antibiotic treatment in long-term care: role of the prescriber. JAMA Intern Med (2013) 2.35
National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes (2010) 2.33
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Variation in nursing home antipsychotic prescribing rates. Arch Intern Med (2007) 2.30